DAPK1 (Death Associated Protein Kinase 1)

In summary, we found that H3K27 acetylation-induced lncRNA-DAPK1-IT1 promotes oxidative stress damage caused by I/R through the miR-25-3p/HMGB1 axis. These findings help to improve our understanding of ischemic stroke and provide new therapeutic avenues.

<b></b> The ethanolic extract of <i>Salvadora persica</i> demonstrates promising antioxidant, anti-inflammatory, anti-angiogenic and pro-apoptotic properties, indicating its potential as a natural therapeutic candidate for oral squamous cell carcinoma. These findings provide a strong foundation for further <i>in vivo</i> and preclinical studies to validate its efficacy and safety.

The most frequent methylation related microRNA was miR-296, followed by miR-193 and miR-137. This study for the first time elucidated the scientometric characteristics of all the publications on methylation modification in oral carcinogenesis, and would provide new insights for researchers to comprehend the methylation specific gene profile related OPMD/OSCC.

By combining machine learning and multi-omics bioinformatics approaches, we identified DAPK1 as a novel biomarker for CRC liver metastasis, which has potential implications for prognosis and therapeutic targeting. These findings highlight DAPK1 as a critical driver of metastatic progression and provide a theoretical foundation for the treatment of CRC.

The compound with the most promising results, CP1, can achieve sustained and effective degradation of DAPK1 at a relatively low concentration (DC50 = 0.1196 μM). Overall, our compound CP1 demonstrated strong efficacy in degrading DAPK1 and shows potential for treating neuronal cell death.

DAPK1, PARP1, and BIRC3 demonstrate substantial diagnostic potential for the condition. Employing bioinformatics to explore potential mechanisms aids in elucidating the genetic pathogenesis of NEC and offers valuable insights for future investigations.

Let-7g, miR-9, miR-143, miR-182, and miR-205 emerged as promising biomarkers for outcome prediction in NMIBC. Their integration into liquid biopsy platforms could support non-invasive monitoring and personalized treatment strategies. These findings warrant validation in larger, prospective studies and through functional assays.

From this perspective, we primarily discuss the structure, biological function, and role of DAPK1 in health and disease, as well as the recently identified small molecule inhibitors and activators. This analysis offers valuable insights for advancing research in the DAPK1 field.

We conclude that eliminating class I HDACs with specific PROTACs could be an effective and precise strategy for treating DLBCL that should be further tested for their potential clinical relevance. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

Molecular modeling suggested modes of binding interaction of selected compounds in the DYRK1A and PIM1 catalytic sites that agreed with the experimental binding data. Our results demonstrate that tricyclic isatin oximes could be potential candidates for developing anti-inflammatory drugs with neuroprotective effects for treating neurodegenerative diseases.

Moreover, s-DAPK-1 was found to interact with a variety of proteins involved in tumor progression and gene regulation, including a prion protein and histone H2B type 2-E (H2B2E). This suggests that s-DAPK-1 may perform diverse molecular functions such as regulation of metabolic processes, nucleic acid binding, and mRNA splicing by interacting with different proteins.